GlassScriptPhysician profile
Holly Packard Strain
NPI 1104555010
$1,586.22
in general payments reported to CMS, 2019-2025
16 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $240 · 2024: $882 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $484.41 | 2022-2025 | Farxiga, Lokelma |
| Amgen INC. | $185.34 | 2023-2024 | Krystexxa, Tavneos, Aranesp |
| Novartis Pharmaceuticals Corporation | $159.84 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $158.98 | 2024 | Strensiq |
| Otsuka America Pharmaceutical, INC. | $116.21 | 2022-2025 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.80 | 2024 | |
| Glaxosmithkline, LLC. | $74.69 | 2023-2025 | Benlysta |
| Akebia Therapeutics INC | $61.46 | 2025 | Vafseo |
| Lilly USA, LLC | $46.69 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $45.44 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $35.62 | 2023-2024 | Tarpeyo |
| Apellis Pharmaceuticals, INC. | $29.59 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $27.75 | 2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $27.39 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.88 | 2023 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Strain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.